Serum hepatocyte growth factor as a predictor of disease severity and future exacerbations in patients with non-cystic fibrosis bronchiectasis - 18/08/21
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
Abstract |
Background |
Serum biomarkers associated with the severity of non-cystic fibrosis (CF) bronchiectasis are insufficient. This study determined the association of serum hepatocyte growth factor (HGF), osteopontin, and pentraxin-3 levels with disease severity and exacerbation in patients with non-CF bronchiectasis.
Methods |
Serum levels of HGF, osteopontin, and pentraxin-3 were measured in patients with clinically stable non-CF bronchiectasis (n = 61). The correlation between the biomarkers and bronchiectasis severity index (BSI) and FACED score was assessed using univariate and multivariate linear regression analyses. Predictive variables associated with exacerbation were analyzed using a Cox proportional hazards model and the time to first exacerbation in high and low HGF groups during the observation period was compared using Kaplan-Meier survival curves.
Results |
The BSI showed significant correlation with HGF (r = 0.423; p = 0.001) and pentraxin-3 (r = 0.316; p = 0.013). The FACED score was significantly correlated with HGF (r = 0.406; p = 0.001). Univariate and multivariate linear regression analysis revealed that serum level of HGF was independently associated with both scoring systems. The high HGF group showed a significantly shorter time to first exacerbation (Log-rank test, p = 0.014). Multivariate Cox proportional hazards regression analysis revealed that high serum HGF level and colonization with non-pseudomonas organisms were independent predictors of future exacerbations (HR 2.364; p = 0.024 and HR 2.438; p = 0.020, respectively).
Conclusion |
Serum level of HGF is a potential biomarker that is closely associated with disease severity and future risk of exacerbations in patients with non-CF bronchiectasis.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Serum level of Hepatocyte Growth Factor (HGF) is associated with severity of non-CF bronchiectasis. |
• | Serum levels of Osteopontin and Pentraxin-3 are unlikely associated with severity of bronchiectasis. |
• | HGF level in stable status can predict acute exacerbation in bronchiectasis patients. |
Keywords : Hepatocyte growth factor, Pentraxin-3, Osteopontin, Non-cycstic fibrosis bronchiectasis, FACED score, Bronchiectasis severity index, Exacerbation
Plan
Vol 185
Article 106505- août 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?